AEON Biopharma Phase 2 migraine trial misses primary endpoint; secondary endpoints statistically significant

AEON Biopharma, Inc.

Primary endpoint not met: mean MMD reduction of 4.8 days (150U) and 5.0 days (195U) vs 4.2 days placebo; p-values not significant (0.2844, 0.1711).
Secondary endpoint: 69% of 195U dose achieved ≥50% MMD reduction vs 52% placebo (p=0.0132); 75% reduction significant for both doses.
Safety profile favorable; Company plans to advance to Phase 3 and request end-of-phase 2 FDA meeting in H1 2024.
Ongoing Phase 2 for chronic migraine to complete enrollment in Q4 2023; topline data expected in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.